Lapatinib- 13 C,d 7

Overview

Lapatinib - 13 C,d 7 (GW572016- 13 C,d 7 ) is the deuterium and 13 C-labeled Lapatinib ( HY-50898 ). Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC 50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Others | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Isotope-Labeled Compounds | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > EGFR

Product Information

• Catalog No.: HY-50898S5
• CAS No.: 1210608-87-9
• Molecular Formula: C2813CH19D7ClFN4O4S
• Molecular Weight: 589.09
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source